May 12, 2020 / 10:25 AM / 21 days ago

BRIEF-Kiadis Pharma Announces New Data Validating PM21 K-NK-Cell Platform

May 12 (Reuters) - Kiadis Pharma NV:

* WE LOOK FORWARD TO INITIATING THE RECENTLY APPROVED PHASE 2 NK-REALM STUDY AND TREATING THE FIRST PATIENTS WITH K-NK CELLS INDUSTRIALLY PRODUCED WITH PM21 - CEO

* ANNOUNCES NEW DATA VALIDATING AND ENHANCING ITS PM21 K-NK-CELL PLATFORM PRESENTED TODAY AT ASGCT VIRTUAL ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below